Zacks Investment Research on MSN

VKTX completes enrollment in phase I maintenance study of obesity drug

Viking Therapeutics VKTX announced that it has completed enrolling patients in its exploratory maintenance dosing study of ...
Morningstar

Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-1 Trial of VK2735

SAN DIEGO, Nov. 19, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and ...
Seeking Alpha

Viking Therapeutics to Highlight Data from Phase 1 Clinical Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Oral Presentation at ObesityWeek 2023

Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders, ...
24/7 Wall St

Viking Therapeutics Could Be Pharma’s Next Big Buyout Target

GLP-1 market growth is fueling Viking Therapeutics‘ (VKTX) momentum with VK2735 in Phase 3 and VK2809’s NASH success. Viking is advancing dual therapies amid a $150 billion obesity opportunity. With a ...